产品
编 号：F096334
分子式：C13H17NaO2
分子量：228.26
分子式：C13H17NaO2
分子量：228.26
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
结构图
CAS No: 1254472-97-3
产品详情
生物活性：
Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84. Fezagepras sodium decreases renal, liver and pancreatic fibrosis. Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions.
体内研究：
Fezagepras sodium (100 mg/kg/天；从 8 -20 周龄开始灌胃) 显著降低 2 型糖尿病患者的高血糖并显著改善 eNOS-/-db/db 小鼠葡萄糖耐量。Animal Model:Type 2 diabetes eNOS-/-db/db mice
Dosage:100 mg/kg/day
Administration:Given via daily gavage from 8-20 weeks
Result:Compared with vehicle-treated mice, hyperglycemia was markedly decreased, and glucose tolerance was markedly improved.
体外研究：
Fezagepras sodium (500 μM；24 小时) 抑制 TGF-β (10 ng/mL) 激活的人肝星状细胞 (HSC) 增殖。 Fezagepras sodium (250 或 500 μM；24 小时) 以剂量依赖性方式将 HSC 阻滞在 G0/G1 期，而不诱导细胞凋亡。
Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84. Fezagepras sodium decreases renal, liver and pancreatic fibrosis. Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions.
体内研究：
Fezagepras sodium (100 mg/kg/天；从 8 -20 周龄开始灌胃) 显著降低 2 型糖尿病患者的高血糖并显著改善 eNOS-/-db/db 小鼠葡萄糖耐量。Animal Model:Type 2 diabetes eNOS-/-db/db mice
Dosage:100 mg/kg/day
Administration:Given via daily gavage from 8-20 weeks
Result:Compared with vehicle-treated mice, hyperglycemia was markedly decreased, and glucose tolerance was markedly improved.
体外研究：
Fezagepras sodium (500 μM；24 小时) 抑制 TGF-β (10 ng/mL) 激活的人肝星状细胞 (HSC) 增殖。 Fezagepras sodium (250 或 500 μM；24 小时) 以剂量依赖性方式将 HSC 阻滞在 G0/G1 期，而不诱导细胞凋亡。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备